4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Lung Cancer by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 8834 ongoing clinical trials involving Lung Cancer
Of the 8834 trials,2383 trials are in Phase II
Furthermore, 2207 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Lung Cancer by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Lung Cancer, an Oncology condition. The largest number of ongoing clinical trials for Lung Cancer is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Lung Cancer-related drug trials.

National Cancer Institute US: The leading ongoing Lung Cancer related clinical trial sponsor

National Cancer Institute US is the top sponsor for Lung Cancer-related ongoing clinical trials.

AstraZeneca Plc, Sun Yat-sen University, University of Texas MD Anderson Cancer Center, F. Hoffmann-La Roche Ltd, and Pfizer Inc are among other notable clinical trial sponsors involved in Lung Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Lung Cancer

Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Bevacizumab (Avastin) are among the key marketed drugs involving Lung Cancer.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as a lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Merck Sharp & Dohme Corp.

Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Opdivo is formulated as solution and concentrate solution for intravenous route of administration. Nivolumab is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Opdivo is indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Nivolumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, and China, by Bristol-Myers Squibb Co.